Drug Profile
Research programme: anticancer therapeutics - Array BioPharma/Novelion Therapeutics
Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma; QLT
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
- 29 Jun 2006 No development reported - Preclinical for Cancer in USA (unspecified route)